Suppr超能文献

微小RNA在肝癌干细胞中的治疗靶点

The Therapeutic Targets of miRNA in Hepatic Cancer Stem Cells.

作者信息

Bimonte Sabrina, Leongito Maddalena, Barbieri Antonio, Del Vecchio Vitale, Falco Michela, Giudice Aldo, Palaia Raffaele, Albino Vittorio, Di Giacomo Raimondo, Petrillo Antonella, Granata Vincenza, Izzo Francesco

机构信息

Division of Abdominal Surgical Oncology, Hepatobiliary Unit, National Cancer Institute "G. Pascale Foundation" IRCCS, 80131 Naples, Italy.

Animal Facility Unit, National Cancer Institute of Naples "G. Pascale Foundation" IRCCS, 80131 Naples, Italy.

出版信息

Stem Cells Int. 2016;2016:1065230. doi: 10.1155/2016/1065230. Epub 2016 Mar 28.

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide malignancy and the third leading cause of cancer death in patients. Several studies demonstrated that hepatic cancer stem cells (HCSCs), also called tumor-initiating cells, are involved in regulation of HCC initiation, tumor progression, metastasis development, and drug resistance. Despite the extensive research, the underlying mechanisms by which HCSCs are regulated remain still unclear. MicroRNAs (miRNAs) are able to regulate a lot of biological processes such as self-renewal and pluripotency of HCSCs, representing a new promising strategy for treatment of HCC chemotherapy-resistant tumors. In this review, we synthesize the latest findings on therapeutic regulation of HCSCs by miRNAs, in order to highlight the perspective of novel miRNA-based anticancer therapies for HCC treatment.

摘要

肝细胞癌(HCC)是全球第五大常见癌症恶性肿瘤,也是患者癌症死亡的第三大主要原因。多项研究表明,肝癌干细胞(HCSCs),也称为肿瘤起始细胞,参与了肝癌的起始、肿瘤进展、转移发展和耐药性的调控。尽管进行了广泛的研究,但HCSCs的调控潜在机制仍不清楚。微小RNA(miRNAs)能够调控许多生物学过程,如HCSCs的自我更新和多能性,这代表了一种治疗肝癌化疗耐药肿瘤的新的有前景的策略。在本综述中,我们综合了miRNAs对HCSCs治疗调控的最新发现,以突出基于新型miRNA的抗癌疗法治疗HCC的前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c3d/4826947/475f78773a4d/SCI2016-1065230.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验